Citadel Advisors LLC raised its holdings in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 1,162.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 126,635 shares of the company’s stock after purchasing an additional 116,602 shares during the quarter. Citadel Advisors LLC owned 0.28% of PMV Pharmaceuticals worth $4,326,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of PMVP. OLD Mission Capital LLC acquired a new stake in PMV Pharmaceuticals during the 3rd quarter valued at approximately $1,835,000. Goldman Sachs Group Inc. bought a new position in PMV Pharmaceuticals during the 1st quarter valued at $2,659,000. Nuveen Asset Management LLC boosted its stake in PMV Pharmaceuticals by 23.7% during the 1st quarter. Nuveen Asset Management LLC now owns 61,858 shares of the company’s stock valued at $2,034,000 after acquiring an additional 11,841 shares during the last quarter. Ameriprise Financial Inc. raised its stake in PMV Pharmaceuticals by 379.4% during the first quarter. Ameriprise Financial Inc. now owns 17,319 shares of the company’s stock valued at $570,000 after buying an additional 13,706 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new stake in PMV Pharmaceuticals during the first quarter valued at approximately $3,926,000. Hedge funds and other institutional investors own 87.39% of the company’s stock.
PMVP has been the subject of several recent research reports. Zacks Investment Research upgraded shares of PMV Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, November 18th. Guggenheim started coverage on PMV Pharmaceuticals in a research note on Monday, August 2nd. They issued a “buy” rating and a $56.00 target price for the company. Oppenheimer started coverage on PMV Pharmaceuticals in a research note on Thursday, August 19th. They issued a “market perform” rating for the company. The Goldman Sachs Group upgraded shares of PMV Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $35.00 to $43.00 in a research report on Wednesday, September 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $62.00 price target on shares of PMV Pharmaceuticals in a report on Monday, November 15th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, PMV Pharmaceuticals presently has an average rating of “Buy” and an average price target of $48.25.
PMV Pharmaceuticals (NASDAQ:PMVP) last announced its earnings results on Friday, November 12th. The company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). Analysts anticipate that PMV Pharmaceuticals, Inc. will post -1.18 earnings per share for the current fiscal year.
In other news, Director Thilo Schroeder sold 13,233 shares of the business’s stock in a transaction on Monday, August 30th. The stock was sold at an average price of $30.05, for a total transaction of $397,651.65. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Arnold J. Levine sold 3,500 shares of PMV Pharmaceuticals stock in a transaction that occurred on Wednesday, September 22nd. The stock was sold at an average price of $30.00, for a total transaction of $105,000.00. The disclosure for this sale can be found here. Insiders have sold 115,275 shares of company stock valued at $3,489,772 in the last ninety days. Company insiders own 21.80% of the company’s stock.
PMV Pharmaceuticals Company Profile
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function.
Featured Article: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.